Litcius/Paper detail

OP0266 EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL

Yannick Allanore, A. M. Hoffmann-Vold, Maureen D. Mayes, Madelon C Vonk, Corinna Miede, M. Alves, G. Riemekasten

2021Annals of the Rheumatic Diseases24 citationsDOI

Topics & Concepts

MedicineNintedanibVital capacityInternal medicinePlaceboInterstitial lung diseaseIdiopathic pulmonary fibrosisScleroderma (fungus)GastroenterologySurgeryLungDiffusing capacityPathologyLung functionInoculationAlternative medicineSystemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedical Imaging and Pathology Studies
OP0266 EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL | Litcius